Lixte Biotechnology Holdings, Inc.

Filed Date	Form Type	Description	View
09/19/2019	Form CT ORDER	Confidential treatment order
08/06/2019	Form 10-Q	Quarterly Report
08/06/2019	Form 8-K	Current Report
05/09/2019	Form 10-Q	Quarterly Report
03/25/2019	Form 10-K	Annual Report
12/12/2018	Form D	Notice of Exempt Offering of Securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
12/05/2018	Form 8-K	Current Report
11/08/2018	Form 10-Q	Quarterly Report
11/07/2018	Form 8-K	Current Report
09/17/2018	Form CT ORDER	Confidential treatment order
08/23/2018	Form 8-K	Current Report
08/14/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
08/14/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
08/09/2018	Form 8-K	Current Report
08/02/2018	Form 10-Q	Quarterly Report
04/27/2018	Form 10-Q	Quarterly Report
03/23/2018	Form 10-K	Annual Report
11/09/2017	Form 10-Q	Quarterly Report
08/04/2017	Form 10-Q	Quarterly Report
05/10/2017	Form 10-Q	Quarterly Report
04/26/2017	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
04/17/2017	Form 3	Initial Statement of Beneficial Ownership of Securities
04/13/2017	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
04/10/2017	Form 8-K	Current Report
03/29/2017	Form 10-K	Annual Report
02/28/2017	Form 8-K	Current Report
01/12/2017	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
01/12/2017	Form 4	Statement of changes in beneficial ownership of securities
12/29/2016	Form 8-K	Current Report
11/28/2016	Form 8-K	Current Report
11/04/2016	Form 10-Q	Quarterly Report
08/10/2016	Form 10-Q	Quarterly Report
06/07/2016	Form 3	Initial statement of beneficial ownership of securities
06/07/2016	Form 4	Statement of changes in beneficial ownership of securities
05/17/2016	Form 8-K	Current Report
05/06/2016	Form10-Q	Quarterly Report
03/28/2016	Form 10-K	Annual Report
02/19/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
02/04/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
02/03/2016	Form 8-K	Current Report
01/26/2016	Form 8-K	Current Report
01/22/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
01/22/2016	Form SC 13G/A	[Amend] Statement of Acquisition of Beneficial Ownership by Individuals
12/30/2015	Form 8-K	Current Report
11/10/2015	Form 10-Q	Current Report
11/10/2015	Form 8-K	Current Report
09/18/2015	Form 8-K	Current Report
09/04/2015	Form SC 13G	Statement of Acquisition of Beneficial Ownership by Individuals
09/03/2015	Form 3	Initial Statement of Beneficial Owenership of Securities
09/03/2015	Form 3	Initial Statement of Beneficial Owenership of Securities
08/07/2015	Form 10-Q	Quarterly Report
08/06/2015	Form SC 13D	General Statement of Acquisition of Beneficial Ownership
08/05/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
06/05/2015	Form SC 13G/A	[Amend] Statement of Acquisition of Beneficial Ownership by Individuals
05/13/2015	Form 10-Q	Quarterly Report
03/27/2015	Form 10-K	Annual Report
03/19/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
03/19/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
03/18/2015	Form 8-K	Current Report
03/04/2015	Form 8-K	Current Report
01/23/2015	Form 8-K	Current Report
11/12/2014	Form 10-Q	Quarterly Report
08/08/2014	Form 10-Q	Quarterly Report
05/21/2014	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
05/21/2014	Form 3	Statement of acquisition of beneficial ownership by individuals
05/14/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
05/14/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
05/12/2014	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
05/12/2014	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
05/09/2014	Form 10-Q	Quarterly Report
04/18/2014	Form 8-K	Current Report
03/21/2014	Form 10-K	Annual Report
11/13/2013	Upload	SEC-Generated Letter
11/07/2013	Form 10-Q	Quarterly Report
10/08/2013	Corresp	Correspondence
09/30/2013	Corresp	Correspondence
09/16/2013	Upload	SEC-Generated Letter
08/05/2013	Form 10-Q	Quarterly Report
05/09/2013	Form 10-Q	Quarterly Report
03/15/2013	Form 10-K	Annual Report
03/14/2013	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

Recent Financial News for LIXT Headline The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings' LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas GlobeNewswire (Aug 06, 2019) First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome GlobeNewswire (Jul 18, 2019) Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder GlobeNewswire (Jun 25, 2019) Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors GlobeNewswire (May 15, 2019) FDA Approves Lixte Biotechnology's IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center GlobeNewswire (Nov 05, 2018) Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center GlobeNewswire (Oct 09, 2018) Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome GlobeNewswire (Aug 21, 2018) Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology's Board of Directors GlobeNewswire (Aug 08, 2018) LB-100 and LB-102, Lixte Biotechnology's Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors GlobeNewswire (Feb 09, 2018) Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model Marketwired (Apr 17, 2017) Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting Marketwired (Mar 09, 2017) First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research Marketwired (Jan 04, 2017) Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors Marketwired (Jun 07, 2016) Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression Marketwired (Feb 03, 2016) Lixte Completes Private Placement of Convertible Preferred Stock Marketwired (Jan 25, 2016) Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University PRNewswire (Dec 30, 2015) Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity PRNewswire (Nov 06, 2015) Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds PRNewswire (Sep 17, 2015) Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University PRIME NEWSWIRE (Jan 11, 2007)